Patient-reported genitourinary dysfunction after laparoscopic and open rectal cancer surgery in a randomized trial (COLOR II)

J. Andersson1,2, G. Abis3, M. Gellerstedt1, E. Angenete1, U. Angerås1, M. A. Cuesta3, P. Jess4, J. Rosenberg5, H. J. Bonjer3 and E. Haglind1

1Scandinavian Surgical Outcomes Research Group, Department of Surgery, Sahlgrenska University Hospital/Östra, Sahlgrenska Academy, Gothenburg University, Gothenburg, and 2Department of Surgery, Alingsås Hospital, Alingsås, Sweden, 3Department of Surgery, VU University Medical Centre, Amsterdam, The Netherlands, and Departments of Surgery, 4Roskilde Hospital, Roskilde, and 1Herlev Hospital, Copenhagen University, Copenhagen, Denmark

Correspondence to: Dr J. Andersson, Scandinavian Surgical Outcomes Research Group, Department of Surgery, Sahlgrenska University Hospital/Östra, SE-416 85 Gothenburg, Sweden (e-mail: john.andersson@vgregion.se)

Background: This article reports on patient-reported sexual dysfunction and micturition symptoms following a randomized trial of laparoscopic and open surgery for rectal cancer.

Methods: Patients in the COLOR II randomized trial, comparing laparoscopic and open surgery for rectal cancer, completed the European Organization for Research and Treatment of Cancer (EORTC) QLQ-CR38 questionnaire before surgery, and after 4 weeks, 6, 12 and 24 months. Adjusted mean differences on a 100-point scale were calculated using changes from baseline value at the various time points in the domains of sexual functioning, sexual enjoyment, male and female sexual problems, and micturition symptoms.

Results: Of 617 randomized patients, 385 completed this phase of the trial. Their mean age was 67.1 years. Surgery caused an anticipated reduction in genitourinary function after 4 weeks, with no significant differences between laparoscopic and open approaches. An improvement in sexual dysfunction was seen in the first year, but some male sexual problems persisted. Before operation 64.5 per cent of men in the laparoscopic group and 55.6 per cent in the open group reported some degree of erectile dysfunction. This increased to 81.1 and 80.5 per cent respectively 4 weeks after surgery, and 76.3 versus 75.5 per cent at 12 months, with no significant differences between groups. Micturition symptoms were less affected than sexual function and gradually improved to preoperative levels by 6 months. Adjusting for confounders, including radiotherapy, did not change these results.

Conclusion: Sexual dysfunction is common in patients with rectal cancer, and treatment (including surgery) increases the proportion of patients affected. A laparoscopic approach does not change this.

Registration number: NCT0029779 (http://www.clinicaltrials.gov).

Presented in part to the Annual Meeting of the European Society of Coloproctology, Belgrade, Serbia, September 2013

Paper accepted 9 April 2014
Published online 12 June 2014 in Wiley Online Library (www.bjs.co.uk). DOI: 10.1002/bjs.9550

Introduction

Studies of laparoscopy in colonic cancer have shown less postoperative pain, faster recovery and improved health-related quality of life (HRQL), with cancer survival rates comparable to those after open surgery1–4. In regard to rectal cancer, several studies describing laparoscopic total mesorectal excision (TME) have been published, with surrogate markers indicating that it is a safe procedure. No definitive long-term survival data are yet available1,5,6.

Traditional primary outcome measures for evaluating laparoscopic surgery for rectal cancer were survival and local recurrence. However, secondary measures such as quality of life, including sexual and urinary dysfunction, are also important7–9. Nerve pathways as well as microvasculature are damaged by radiotherapy, and this can be compounded by surgery10–14. Sexual dysfunction after open rectal surgery has been reported in between 10 and 35 per cent of patients, but urinary dysfunction is present in less than 5 per cent15,16. Reports17–19 of sexual and urinary
dysfunction after laparoscopic TME are conflicting, indicating that more research is warranted.

The aim of this study was to compare patient-reported sexual dysfunction and micturition symptoms after rectal cancer surgery in a randomized clinical trial (COlorectal cancer Laparoscopic or Open Resection, COLOR II).

**Methods**

COLOR II, a non-inferiority, international, randomized clinical trial, included patients in 30 hospitals. Patients with a single rectal cancer within 15 cm from the anal verge were included, in a 2:1 ratio of laparoscopic to open. Patients with tumours invading adjacent tissues or organs, T4 tumours, or T3 rectal cancers within 2 mm of the endopelvic fascia at preoperative evaluation, were excluded. Further details about inclusion and exclusion criteria, randomization and clinical short-term outcomes have been reported previously. The protocol of the COLOR II trial was approved by the appropriate ethics committees and registered at ClinicalTrials.gov (NCT00297779).

**Quality-of-life measurements**

Twelve hospitals in five countries (Canada, Denmark, Germany, The Netherlands and Sweden) participated in the optional HRQL component of the COLOR II trial. Inability to understand the questionnaires was an exclusion criterion. Patients who agreed to participate were asked to fill in the preoperative questionnaire before surgery. After operation the questionnaires were sent out at 4 weeks, and 6, 12 and 24 months.

Demographic data, details of preoperative radiotherapy and chemotherapy, complications during and after surgery, and the pathology report on the resected specimen were used from the clinical record forms (CRFs). At the follow-up visits (12 and 24 months), the surgeon recorded the presence of sexual dysfunction and stress urinary incontinence in the CRF.

Validated Swedish, Dutch, Danish, English and German translations of the European Organization for the Treatment of Cancer (EORTC) questionnaire QLQ-CR38 were used. This questionnaire is designed for self-administration and measures specific information about quality of life in patients with colorectal cancer. Thirty-eight questions are divided into four functional scales/single items (body image, sexual functioning, sexual enjoyment, future perspective) and eight symptom scales/items (micturition symptoms, chemotherapy side-effects, symptoms in the area of the gastrointestinal tract, male sexual problems, female sexual problems, defaecation problems, stomal-related problems and weight loss).

For this study the domains/scales/items sexual functioning, sexual enjoyment, male sexual problems, female sexual problems and micturition symptoms were used. All questions relate to the previous 4 weeks and have four alternative responses: ‘not at all’, ‘a little’, ‘quite a bit’ and ‘very much’. The sexual functioning item comprises two questions: ‘To what extent were you sexually active (with or without intercourse)?’ and ‘To what extent were you interested in sex?’. The answers were dichotomized into ‘not at all’ versus the rest (‘a little’, ‘quite a bit’, ‘very much’) to gauge sexual activity and sexual interest. The single item of sexual enjoyment is answered only if the patient has been sexually active. The symptom scale for male sexual problems has two items: ‘Did you have difficulty getting or maintaining an erection?’ and ‘Did you have problems with ejaculation (such as so-called dry ejaculation)?’.

| Table 1 | Response frequencies for functioning domains and symptom scales in EORTC QLQ-CR38 at different time points |
|---------|----------------------------------------------------------------------------------------------------------|
|         | Preop. | 4 weeks | 6 months | 12 months | 24 months |
| Sexual functioning (n = 385) | | | | | |
| Laparoscopic | 326 (84.7) | 305 (79.2) | 302 (78.4) | 286 (74.3) | 205 (53.2) |
| Open | 102 | 98 | 96 | 89 | 64 |
| Sexual enjoyment (n = 385) | | | | | |
| Laparoscopic | 147 (38.2) | 58 (15.1) | 109 (28.3) | 125 (32.5) | 62 (16.1) |
| Open | 56 | 21 | 37 | 38 | 21 |
| Male sexual problems (n = 239) | | | | | |
| Laparoscopic | 178 (74.6) | 132 (55.2) | 163 (68.2) | 167 (69.9) | 115 (48.1) |
| Open | 54 | 41 | 47 | 50 | 37 |
| Female sexual problems (n = 146) | | | | | |
| Laparoscopic | 38 (26.0) | 13 (8.9) | 29 (19.9) | 33 (22.6) | 12 (8.2) |
| Open | 15 | 10 | 19 | 19 | 7 |
| Micturitional symptoms (n = 385) | | | | | |
| Laparoscopic | 350 (90.9) | 322 (83.6) | 320 (83.1) | 304 (79.0) | 249 (64.7) |
| Open | 110 | 103 | 101 | 95 | 79 |

Values in parentheses are percentages. EORTC, European Organization for Research and Treatment of Cancer.
Assessed for eligibility: patients in COLOR II in hospitals participating in HRQL study n = 617

Possible for inclusion in HRQL study n = 584

Randomized 2 : 1 (laparoscopic : open) n = 385

Laparoscopic resection n = 260

Open resection n = 125

Excluded from COLOR II n = 33

Did not participate (no informed consent, language difficulties, cognitive disability, logistical difficulties) n = 199

Fig. 1 Study flow chart. COLOR, COlorectal cancer Laparoscopic or Open Resection; HRQL, health-related quality of life

Table 2 Preoperative demographics for the health-related quality-of-life study group and those not included

|                          | Not included in HRQL study (n = 199) | Included in HRQL study (n = 385) | P†       | Laparoscopic (n = 260) | Open (n = 125) | P†       |
|--------------------------|-------------------------------------|---------------------------------|----------|------------------------|---------------|----------|
| Age (years)*             | 67.0 (66.0, 69.4)                   | 67.1 (66.1, 68.1)               | 0.696‡   | 67.4 (66.1, 68.6)      | 66.6 (64.8, 68.4) | 0.487§   |
| Sex ratio (M:F)          | 123:76                              | 239:146                         | 0.949‡   | 162:98                 | 77:48         | 0.893‡   |
| BMI (kg/m²)*             | 25.9 (25.3, 26.5)                   | 26.0 (25.6, 26.5)               | 0.750‡   | 26.0 (25.4, 26.6)      | 26.1 (25.3, 26.8) | 0.698§   |
| ASA grade                |                                     |                                 |          |                        |               |          |
| I                        | 37 (18.6)                           | 103 (26.8)                      |          | 69 (26.5)              | 34 (27.2)     |          |
| II                       | 101 (50.8)                          | 224 (58.2)                      |          | 149 (57.3)             | 75 (60.0)     |          |
| III                      | 48 (24.1)                           | 55 (14.3)                       |          | 40 (15.4)              | 15 (12.0)     |          |
| IV                       | 1 (0.5)                             | 2 (0.5)                         |          | 2 (0.8)                | 0 (0)         |          |
| Unknown                  | 12 (6.0)                            | 1 (0.3)                         |          | 0 (0)                  | 1 (0.8)       |          |
| Tumour stage†            |                                     |                                 | 0.262‡   | 0.552                  |               |          |
| I                        | 8 (4.0)                             | 22 (5.7)                        |          | 18 (6.9)               | 4 (3.2)       |          |
| II                       | 71 (35.7)                           | 135 (35.1)                      |          | 93 (35.8)              | 42 (33.6)     |          |
| III                      | 101 (50.8)                          | 207 (53.8)                      |          | 135 (51.9)             | 72 (57.6)     |          |
| IV                       | 7 (3.5)                             | 12 (3.1)                        |          | 9 (3.5)                | 3 (2.4)       |          |
| Unknown                  | 12 (6.0)                            | 9 (2.3)                         |          | 5 (1.8)                | 4 (3.2)       |          |

Values in parentheses are percentages unless indicated otherwise; *values are mean (95 per cent confidence interval). †Stage in the pathology report of the resected specimen. HRQL, health-related quality of life; BMI, body mass index; ASA, American Society of Anesthesiologists. ‡χ² test, except §Student’s t test.

the symptom scale for female sexual problems, answered only by women who have had sexual intercourse, the items are: ‘Did you have a dry vagina during intercourse?’ and ‘Did you have pain during intercourse?’ The individual QLQ-CR38 scores were handled according to the EORTC scoring manual and converted to a score ranging from 0 to 100. A high score on the symptom/item scales represents a high level of symptoms/problems, whereas a high score on the functioning scales represents a high level of functioning.
Table 3  Surgical variables for the health-related quality-of-life study group and those not included

|                          | Not included in HRQL study (n = 198) | Included in HRQL study (n = 385) | Laparoscopic (n = 260) | Open (n = 125) | P§ |
|--------------------------|-------------------------------------|---------------------------------|-----------------------|---------------|----|
| Type of resection        |                                     |                                 |                       |               |    |
| PME                      | 15 (7.5)                            | 42 (10.9)                       | 27 (10.4)             | 15 (12.0)     | 0.632 0.956 |
| TME                      | 112 (56.3)                          | 219 (56.9)                      | 147 (56.5)            | 72 (57.6)     | 0.001 0.994 |
| APE                      | 64 (32.2)                           | 116 (30.1)                      | 80 (30.8)             | 36 (28.8)     | 0.001 0.994 |
| Other                    | 3 (1.5)                             | 6 (1.6)                         | 4 (1.5)               | 2 (1.6)       | 0.001 0.994 |
| Unknown                  | 5 (2.5)                             | 2 (0.5)                         | 2 (0.8)               | 0 (0)         | 0.001 0.994 |
| Preoperative radiation   |                                     |                                 |                       |               |    |
| Yes                      | 139 (69.8)                          | 216 (56-1)                      | 150 (57.7)            | 66 (52.8)     | 0.001 0.994 |
| Short§                   | 110 (55.3)                          | 157 (40-8)                      | 110 (42-3)            | 47 (37-6)     | 0.001 0.994 |
| Long§                    | 23 (11.6)                           | 40 (10-4)                       | 27 (10-4)             | 13 (10-4)     | 0.001 0.994 |
| Dose not specified       | 6 (3.0)                             | 19 (4.9)                        | 13 (0.5)              | 6 (4.8)       | 0.001 0.994 |
| No                       | 60 (30-2)                           | 168 (43-6)                      | 110 (42-3)            | 58 (46-4)     | 0.001 0.994 |
| Unknown                  | 0 (0)                               | 1 (0-3)                         | 0 (0)                 | 1 (0-8)       | 0.001 0.994 |
| Preoperative chemotherapy |                                     |                                 |                       |               |    |
| Yes                      | 31 (15.6)                           | 64 (16-6)                       | 44 (16-9)             | 20 (16-0)     | 0.001 0.994 |
| No                       | 145 (72.9)                          | 290 (75-3)                      | 195 (75-0)            | 95 (76-0)     | 0.001 0.994 |
| Unknown                  | 23 (11-6)                           | 31 (8-1)                        | 21 (8-1)              | 10 (8-0)      | 0.001 0.994 |
| Stoma                    |                                     |                                 |                       |               |    |
| Permanent colostomy      | 71 (35-7)                           | 139 (36-1)                      | 96 (36-9)             | 43 (34-4)     | 0.490 |
| Loop ileostomy           | 49 (24-6)                           | 123 (31-9)                      | 84 (32-3)             | 39 (31-2)     | 0.808 |
| Reversed by 1 year       | 29 (59)                             | 45 (36-6)                       | 29 (35)               | 16 (41)       | 0.975 |
| Perioperative nerve preservation | 187 (94-0) | 371 (96-4) | 248 (95-4) | 123 (98-4) | 0.195 0.610 |
| Total preservation       |                                     |                                 |                       |               |    |
| Bilateral                | 0 (0)                               | 2 (0-5)                         | 2 (0-8)               | 0 (0)         | 0.001 0.994 |
| Unilateral               | 4 (2-0)                             | 3 (0-8)                         | 2 (0-8)               | 1 (0-8)       | 0.001 0.994 |
| Other                    | 1 (0-5)                             | 0 (0)                           | 0 (0)                 | 0 (0)         | 0.001 0.994 |
| Unknown                  | 7 (3-5)                             | 9 (2-3)                         | 8 (3-1)               | 1 (0-8)       | 0.001 0.994 |
| Blood loss (ml)*         | 408 (384, 551)                      | 463 (404, 522)                  | 358 (292, 424)        | 676 (566, 786) | < 0.001 |
| Anastomotic leakage      | 22 (11-1)                           | 17 (4-4)                        | 13 (5-0)              | 4 (3-2)       | 0.421 |
| Skin-to-skin time (min)* | 213 (203, 223)                      | 253 (244, 262)                  | 272 (261, 283)        | 213 (201, 226) | < 0.001 |
| Conversion               |                                     | 65 (25-0)                       |                       |               |    |

Values in parentheses are percentages unless indicated otherwise; *values are mean (95 per cent confidence interval). HRQL, health-related quality of life; PME, partial mesorectal excision; TME, total mesorectal excision; APR, abdominoperineal excision using TME dissection. 15 × 5 Gy or less; ‡all programmes more than 5 days. §Χ² test, except ¶Student’s t test.

Statistical analysis

The COLOR II study was powered for the primary end-point of local recurrence at 3 years after index surgery. For this study a post hoc analysis was performed. The sample size achieved (Table 1) corresponds to a power of 80 per cent to detect a difference in change between the two surgical procedures of around 7 points, using Student’s independent-samples t test (5 per cent significance level) and assuming a standard deviation of 20 points in both samples. Applying the same principle to male sexual problems enabled detection of a difference of 10 points (Table 1). The domain sexual enjoyment and the symptom scale female sexual function were not analysed because response rates were low.

In the EORTC questionnaires, several studies have examined the minimal important difference (MID), which represents the difference in scores corresponding to a clinically meaningful difference. Osoba suggested that the MID is in the range of 5–10 points on the 100-point scale and that a difference of more than 20 points suggests a substantial change. Missing data were handled according to instructions in the EORTC score manual.

Results were calculated for the individual patient and expressed as a change from baseline before being presented as means on a group level. Comparisons of groups at baseline were made using Student’s t test, Χ² test and, where appropriate, Fisher’s exact test. Function and symptom scales in the QLQ-CR38 were analysed using ANCOVA with the baseline (preoperative) score as a co-variable and surgical procedure as a factor. The results are presented as mean changes adjusted for baseline with P values and 95 per cent confidence intervals. The perspective of all statistical analyses was intention to treat. The level of significance was set at P < 0.050. All baseline factors and preoperative scores on functioning domains and symptom scales were considered possible confounders. To check for confounders (age, sex, body mass index, American Society of Anesthesiologists (ASA) grade, tumour stage, type of resection, preoperative radiotherapy, preoperative chemotherapy, stoma, blood loss, anastomotic
leakage, duration of operation and conversion), Student’s t test, ANOVA or correlation, where appropriate, were used. Confounders with \( P < 0.200 \) in the bivariate analysis were included in a multiple regression model together with surgical technique. This analysis applied to 12-month data.

All statistical analyses were performed using SPSS® 20 software (IBM, Armonk, New York, USA). Owing to the explorative nature of this study, significant \( P \) values should be interpreted with care, as interesting findings rather than conclusive evidence.

### Results

Between 2004 and 2010, 1103 patients were included in the COLOR II trial; 385 patients (260 laparoscopic and 125 open) were included in this study (Fig. 1). The patients included in the HRQL study had a lower ASA grade, a longer operating time, a smaller proportion had received preoperative radiation, and fewer had postoperative anastomotic leakage compared with the eligible patients who were not included (Tables 2 and 3). Demographic characteristics did not differ between the laparoscopic and open groups.

At 1-year follow-up, sexual dysfunction was registered in the CRFs for 29 of 326 patients (16 laparoscopic and 13 open; data missing for 59). The corresponding proportion at 2-year follow-up was 19 of 263 (11 laparoscopic and 8 open; data missing for 114 and 8 dead). There were no significant differences between the laparoscopic and open groups regarding sexual dysfunction or micturition problems at any time point (Table 4). Adjusting

| Table 4 Changes in functional domains and symptom scale scores in EORTC QLQ-CR38 |
|--------------------------------------|------------------------|------------------------|------------------------|------------------------|
|                                      | 4 weeks                 | 6 months               | 12 months              | 24 months              |
|                                      | Mean preop. score       | Mean change from preop.| Adjusted mean difference* | Mean change from preop.| Adjusted mean difference* | Mean change from preop.| Adjusted mean difference* | Mean change from preop.| Adjusted mean difference* |
| Sexual functioning†                  |                         |                        |                        |                        |                        |                        |                        |                        |                        |
| Laparoscopic                         | 19.9 (16-9, 22-8)       | -11.2                  | -2.5 (-0.3, 6.3)       | -4.2                   | -0.8 (-5.5, 3.9)       | -4.2                   | -0.8 (-5.5, 3.9)       | -1.2                   | -0.8 (-5.5, 3.9)       |
| Open                                 | 24.3 (19.5, 29.2)       | -17.2                  | -5.8                   | -8.2                   | -1.2                   | -6.7                   | -1.2                   | -6.7                   | -6.7                   |
| Sexual enjoyment†                    | 49.1 (42.5, 55.8)       | -8.0                   | -0.7 (-0.4, 18.9)      | -12.9                  | -24.6                  | -12.9                  | -24.6                  | -12.9                  | -24.6                  |
| Laparoscopic                         | 61.3 (52.1, 70.6)       | -11.1                  | -1.4                   | -7.7                   | -16.7                  | -7.7                   | -16.7                  | -7.7                   | -16.7                  |
| Open                                 | 65.1 (55.0, 75.2)       | -12.8                  | -4.4                   | -11.5                  | -18.3                  | -11.5                  | -18.3                  | -11.5                  | -18.3                  |
| Male sexual problems‡                | 36.2 (29.9, 42.4)       | -2.6                   | -6.5 (-19.9, 6.8)      | 22.4                   | 34.2                   | 21.6                   | 36.6                   | 9.8 (-22.3, 2.6)       | 24.1                   |
| Laparoscopic                         | 27.8 (19.7, 35.8)       | -3.8                   | -8.9                   | -20.5, 6.7             | -9.8                   | -22.3, 2.6             | -12.2, 14.4            |
| Open                                 | 38.9                   | -5.6                   | -19.9, 6.8             | 34.2                   | 53.6                   | 22.7                   | -18.9, 42.5            |
| Female sexual problems‡              | 10.9 (4.1, 17.6)        | 11.1                   | 16.7                   | -7.3 (-6.3, 11.7)      | 16.7                   | 16.5, 26.8             | 14.8                   |
| Laparoscopic                         | 12.2 (1.5, 23.0)        | -1.1                   | 16.7                   | 16.7                   | 16.5, 26.8             | 14.8                   |
| Open                                 | 16.7                   | -7.0                   | 16.7                   | 14.8                   |
| Micturition symptoms‡                | 24.0 (21.7, 26.3)       | 9.6                    | 0.9 (-4.4, 6.2)        | 0.5                    | 1.6                    | -1.0 (-5.0, 3.0)       | -1.2                   |
| Laparoscopic                         | 23.3 (20.0, 26.7)       | 9.4                    | 0.9 (-4.4, 6.2)        | 0.5                    | 1.6                    | -1.0 (-5.0, 3.0)       | -1.2                   |
| Open                                 | 20.0                   | -7.3                   | 0.9 (-4.4, 6.2)        | 0.5                    | 1.6                    | -1.0 (-5.0, 3.0)       | -1.2                   |

Values in parentheses are 95 per cent confidence intervals. *Laparoscopic minus open. †A high value indicates a high grade of functioning/enjoyment. ‡A high value means a high grade of symptoms/problems. EORTC, European Organization for Research and Treatment of Cancer.

![Sexual functioning, laparoscopic](image1)

**Fig. 2** Mean scores on European Organization for Research and Treatment of Cancer QLQ-CR38 domains for sexual functioning and sexual enjoyment over time and by surgical technique. A high value on the 100-point scale suggests a high level of functioning.
All aspects of sexual dysfunction and micturition symptoms had deteriorated by 4 weeks after surgery. Sexual functioning showed a pronounced deterioration, but returned to baseline. Sexual enjoyment decreased by 6 months and stayed at a lower level throughout the study (Fig. 2). Male sexual problems increased by 4 weeks after surgery and were relatively stable thereafter (Fig. 3). Changes over time in sexual activity and sexual interest are shown in Fig. 4. Sexual activity was decreased at 4 weeks after surgery, but recovered partially. There were differences between men and women regarding both sexual interest and activity.

Before surgery 64.5% of the men in the laparoscopic group reported some degree of erectile dysfunction compared with 55.6% in the open group (P = 0.253). Corresponding values were 81.1% and 80.5% per cent 4 weeks after surgery (P = 0.933), and 76.3% and 75.5% per cent respectively at 12 months (P = 0.912).

**Discussion**

There were no differences in sexual dysfunction and micturition symptoms after laparoscopic versus open surgery for rectal cancer. Sexual dysfunction was more pronounced than micturition symptoms, regardless of technique. As in previous studies, it was found that women showed less interest and had lower sexual activity than men. In the setting of the randomized Conventional versus Laparoscopic-Assisted Surgery In Colorectal Cancer (CLASICC) trial, in which EORTC QLQ-CR38 questionnaires were collected prospectively and the International Index of Erectile Function (IIEF) was added retrospectively, there were no significant differences in sexual function between laparoscopic and open surgery for rectal cancer. Quah and colleagues reported a significant difference in male sexual dysfunction between patients undergoing laparoscopic and open rectal cancer surgery, in favour of open surgery. That study was based on retrospective interviews and questionnaires (IIEF) 3 years after surgery for about 50% of the patients in a randomized trial, and the results should be evaluated in view of these methodological shortcomings. In a retrospective study of 173 patients treated in a single centre by an expert laparoscopic surgeon, there was a significant difference in sexual function in favour of laparoscopic compared with open surgery. As previously indicated by Stephens and colleagues, radiotherapy has less effect on sexual dysfunction than surgery.

The main strengths of the present study are the prospective and randomized design, population size, collection of baseline data, reporting of HRQL at several time points,
and the use of validated and established instruments. The weaknesses include that the HRQL part of the COLOR II study was optional for participating centres and had a relatively low inclusion rate (62.4 per cent of those eligible), with a small but significant selection bias regarding ASA grade, preoperative radiation, rate of anastomotic leakage and duration of operation between eligible patients who did not participate and included patients. There were differences between the laparoscopic and open surgery groups in operating time and blood loss, concordant with findings in the total COLOR II trial cohort.

The same group of patients had a response rate of approximately 90 per cent for other parts of the QLQ-CR38 questionnaire, whereas for the scales or symptoms reported in this study the response rates varied between 8.2 and 90.9 per cent. In the EORTC instrument there is a structural problem regarding the symptom scale female sexual problems as the questions are tied to the condition of sexual intercourse during the past 4 weeks. This may in part explain the low response to this symptom scale. Owing to its international design, this study was restricted to using instruments validated in many languages. The instrument has a heteronormative approach with sexual penetration as the norm. On the other hand, it is possible that some patients may be offended by sexual questions insinuating homosexual behaviour or masturbation, which could influence the response rates.

The low frequency of CRF-reported complications regarding sexual dysfunction contrasted with the higher frequency of problems reported by patients in the questionnaires. This emphasizes the need for patient-reported outcomes as a complement to the surgeon’s records when evaluating postoperative morbidity.

Acknowledgements

This study received financial support from the Swedish Cancer Foundation, Region Västra Götaland, Sahlgrenska University Hospital (ALF grant 138751, agreement concerning research and education of doctors), the Swedish Research Council, Alice Swenson Foundation, Anna-Lisa and Bror Björnssons Foundation, Assar Gabrielsson Foundation, the Foundation of Rehabilitation and Medical Research, and the Gothenburg Medical Society.

Disclosure: The authors declare no conflict of interest.

References

1. Veldkamp R, Kuhry E, Hop WC, Jeekel J, Kazemier G, Bonjer HJ et al. Laparoscopic surgery versus open surgery for colon cancer: short-term outcomes of a randomised trial. Lancet Oncol 2005; 6: 477–484.
2. Buunen M, Veldkamp R, Hop WC, Kuhry E, Jeekel J, Haglind E et al.; Colon Cancer Laparoscopic or Open Resection Study Group. Survival after laparoscopic surgery versus open surgery for colon cancer: long-term outcome of a randomised clinical trial. Lancet Oncol 2009; 10: 44–52.
3. van der Pas MH, Haglind E, Cuesta MA, Fürst A, Lacy AM, Hop WC et al.; COlorectal Cancer Laparoscopic or Open Resection II (COLOR II) Study Group. Laparoscopic versus open surgery for rectal cancer (COLOR II): short-term outcomes of a randomised, phase 3 trial. Lancet Oncol 2013; 14: 210–218.
4. Janson M, Lindholm F, Anderb erg B, Haglind E. Randomized trial of health-related quality of life after open and laparoscopic surgery for colon cancer. Surg Endosc 2007; 21: 747–753.
5. Jayne DG, Guillou PJ, Thorpe H, Quirke P, Copeland J, Smith AM et al. Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC Trial Group. J Clin Oncol 2007; 25: 3061–3068.
6. Ng SS, Lee JF, Yiu RY, Li JC, Hon SS, Mak TW et al. Long-term oncologic outcomes of laparoscopic versus open surgery for rectal cancer: a pooled analysis of 3 randomized controlled trials. Ann Surg 2014; 259: 139–147.
7. Sprangers MA. Quality-of-life assessment in oncology. Achievements and challenges. Acta Oncol 2002; 41: 229–237.
8. Dowswell G, Ismail T, Greenfield S, Clifford S, Hancock B, Wilson S. Men’s experience of erectile dysfunction after treatment for colorectal cancer: qualitative interview study. BMJ 2011; 343: d5824.
9. Sadovsky R, Basson R, Krychman M, Morales AM, Schover L, Wang R et al. Cancer and sexual problems. J Sex Med 2010; 7: 349–373.
10. Eveno C, Lamblin A, Mariette C, Pocard M. Sexual and urinary dysfunction after proctectomy for rectal cancer. J Vis Surg 2010; 147: e21–e30.
11. Marijn en CA, van de Velde CJ, Putter H, van den Brink M, Maas CP, Martijn H et al. Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol 2005; 23: 1847–1858.
12. Stephens RJ, Thompson LC, Quirke P, Steele R, Greive R, Couture J et al. Impact of short-course preoperative radiotherapy for rectal cancer on patients’ quality of life: data from the Medical Research Council CR07/National Cancer Institute of Canada Clinical Trials Group C016 randomized clinical trial. J Clin Oncol 2010; 28: 4233–4239.
13. Rodrigues AC, Teixeira R, Teixeira T, Conde S, Soares P, Torgal I. Impact of pelvic radiotherapy on female sexuality. Arch Gynecol Obstet 2012; 285: 505–514.
14. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008; 358: 1250–1261.
15 Havenga K, Enker WE, McDermott K, Cohen AM, Minsky BD, Guillem J. Male and female sexual and urinary function after total mesorectal excision with autonomic nerve preservation for carcinoma of the rectum. J Am Coll Surg 1996; 182: 495–502.
16 Hendren SK, O’Connor BI, Liu M, Asano T, Cohen Z, Swallow CJ et al. Prevalence of male and female sexual dysfunction is high following surgery for rectal cancer. Ann Surg 2005; 242: 212–223.
17 Quah HM, Jayne DG, Eu KW, Seow-Choen F. Bladder and sexual dysfunction following laparoscopically assisted and conventional open mesorectal resection for cancer. Br J Surg 2002; 89: 1551–1556.
18 Jayne DG, Brown JM, Thorpe H, Walker J, Quirke P, Guillou PJ. Bladder and sexual function following resection for rectal cancer in a randomized clinical trial of laparoscopic versus open technique. Br J Surg 2005; 92: 1124–1132.
19 Breukink SO, van Driel MF, Pierie JP, Dobbins C, Wiggers T, Meijerink WJ. Male sexual function and lower urinary tract symptoms after laparoscopic total mesorectal excision. Int J Colorectal Dis 2008; 23: 1199–1205.
20 Buunen M, Bonjer HJ, Hop WC, Haglind E, Kurlberg G, Rosenberg J et al. COLOR II. A randomized clinical trial comparing laparoscopic and open surgery for rectal cancer. Dan Med Bull 2009; 56: 89–91.
21 Andersson J, Anzenete E, Gellerstedt M, Angerås U, Jess P, Rosenberg J et al. Health-related quality of life after laparoscopic and open surgery for rectal cancer in a randomized trial. Br J Surg 2013; 100: 941–949.
22 Osoba D. Interpreting the meaningfulness of changes in health-related quality of life scores: lessons from studies in adults. Int J Cancer Suppl 1999; 12: 132–137.
23 Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999; 281: 537–544.
24 McGlone ER, Khan O, Flashman K, Khan J, Parvaiz A. Urogenital function following laparoscopic and open rectal cancer resection: a comparative study. Surg Endosc 2012; 26: 2559–2565.
25 Beckman N, Waern M, Gustafson D, Skoog I. Secular trends in self reported sexual activity and satisfaction in Swedish 70 year olds: cross sectional survey of four populations, 1971–2001. BMJ 2008; 337: a279.

Snapshot quiz

Snapshot quiz 14/13

Answer: This patient was admitted because of a tender irreducible perineal mass. He had an abdominoperineal resection for rectal cancer 9 years previously. The pelvic floor was reconstructed with a gluteal muscle flap. CT shows herniation of small bowel below and behind the sacral bone. At laparotomy, 150 cm of gangrenous small bowel was resected with primary anastomosis. The perineal defect was closed with a biological mesh (porcine collagen). Posterior perineal hernias are only seen as a surgical complication.